Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9897979 | 1.00 | BACE1 (0.38) | BACE1SMYD2 | |
| SCHEMBL9897980 | 1.00 | BACE1 (0.38) | BACE1SMYD2 | |
| SCHEMBL14369931 | 0.83 | BACE1 (0.37) | BACE1SMYD2 | |
| SCHEMBL1444038 | 0.80 | BACE1 (0.43) | BACE1SMYD2 | |
| SCHEMBL5344632 | 0.78 | BACE1 (0.35) | BACE1SMYD2 | |
| SCHEMBL5337630 | 0.78 | BACE1 (0.35) | BACE1SMYD2 | |
| SCHEMBL21827847 | 0.78 | BACE1 (0.40) | BACE1SMYD2 | |
| SCHEMBL6121758 | 0.77 | BACE1 (0.37) | BACE1SMYD2 | |
| SCHEMBL5880292 | 0.77 | BACE1 (0.39) | BACE1SMYD2 | |
| SCHEMBL14461324 | 0.76 | BACE1 (0.43) | BACE1SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376442-B2 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2016-06-28 | — | — | US | disclosed |
| US-20150073001-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| US-8927557-B2 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| EP-2470536-B1 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2014-11-12 | — | — | EP | disclosed |
| EP-2470536-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | Nycomed GmbH (DE) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149721-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149721-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE12, PDE4A | BACE1 2397/4885SMYD2 318/4885 |
| US-20150073001-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | PDE12, PDE5A, PDE4A | BACE1 3953/4885SMYD2 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.